NEW YORK (GenomeWeb) – TAI Diagnostics, a developer of diagnostic tests for monitoring the health of transplanted organs, said on Monday that it has closed a $10 million Series A preferred equity financing.

TAI will use proceeds from the new financing to support ongoing R&D on its PCR-based cell-free DNA transplant monitoring technology, clinical studies, and the upcoming commercial launch of its post-transplant monitoring assays performed in its CLIA- and CAP-accredited laboratory.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.